Supporting this, they found increased caspase-1 activation and IL-1β production in CMML, juvenile myelomonocytic leukemia (JMML) and AML patients with KRAS mutations as compared to patients without KRAS mutations (Hamarsheh et al., 2020). The gene discussed is IL1B; the disease is acute myeloid leukemia.